Pear Therapeutics investor relations material

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company develops and sells software-based medicines that are designed to be used with commercially available sensors and electrocardiogram (EKG) devices. Pear Therapeutics’ software-based medicines apply data-driven machine learning, artificial intelligence, and novel intervention design to provide physicians and patients with personalized, evidence-based medical recommendations for atrial fibrillation (AF) treatment. The company's software is available in more than 200 hospitals across the United States.